JP2018527397A5 - - Google Patents

Download PDF

Info

Publication number
JP2018527397A5
JP2018527397A5 JP2018515050A JP2018515050A JP2018527397A5 JP 2018527397 A5 JP2018527397 A5 JP 2018527397A5 JP 2018515050 A JP2018515050 A JP 2018515050A JP 2018515050 A JP2018515050 A JP 2018515050A JP 2018527397 A5 JP2018527397 A5 JP 2018527397A5
Authority
JP
Japan
Prior art keywords
poly
less
olanzapine
dosage form
pharmaceutical dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018515050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527397A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/052757 external-priority patent/WO2017053346A1/en
Publication of JP2018527397A publication Critical patent/JP2018527397A/ja
Publication of JP2018527397A5 publication Critical patent/JP2018527397A5/ja
Priority to JP2021110240A priority Critical patent/JP2021167331A/ja
Pending legal-status Critical Current

Links

JP2018515050A 2015-09-21 2016-09-21 徐放性オランザピン製剤 Pending JP2018527397A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021110240A JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562221290P 2015-09-21 2015-09-21
US62/221,290 2015-09-21
PCT/US2016/052757 WO2017053346A1 (en) 2015-09-21 2016-09-21 Sustained release olanzapine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021110240A Division JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Publications (2)

Publication Number Publication Date
JP2018527397A JP2018527397A (ja) 2018-09-20
JP2018527397A5 true JP2018527397A5 (cg-RX-API-DMAC7.html) 2019-10-31

Family

ID=57047342

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018515050A Pending JP2018527397A (ja) 2015-09-21 2016-09-21 徐放性オランザピン製剤
JP2021110240A Pending JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021110240A Pending JP2021167331A (ja) 2015-09-21 2021-07-01 徐放性オランザピン製剤

Country Status (21)

Country Link
US (4) US20170079985A1 (cg-RX-API-DMAC7.html)
EP (2) EP4331570A1 (cg-RX-API-DMAC7.html)
JP (2) JP2018527397A (cg-RX-API-DMAC7.html)
KR (1) KR20180054627A (cg-RX-API-DMAC7.html)
CN (2) CN116942677A (cg-RX-API-DMAC7.html)
AR (1) AR106085A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016328958B2 (cg-RX-API-DMAC7.html)
CA (1) CA2998504C (cg-RX-API-DMAC7.html)
CL (1) CL2018000727A1 (cg-RX-API-DMAC7.html)
DK (1) DK3352735T3 (cg-RX-API-DMAC7.html)
EA (1) EA201890788A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960753T3 (cg-RX-API-DMAC7.html)
FI (1) FI3352735T3 (cg-RX-API-DMAC7.html)
HU (1) HUE063850T2 (cg-RX-API-DMAC7.html)
IL (3) IL295161A (cg-RX-API-DMAC7.html)
MX (2) MX2018003380A (cg-RX-API-DMAC7.html)
NZ (1) NZ740665A (cg-RX-API-DMAC7.html)
PL (1) PL3352735T3 (cg-RX-API-DMAC7.html)
PT (1) PT3352735T (cg-RX-API-DMAC7.html)
TW (1) TWI798161B (cg-RX-API-DMAC7.html)
WO (1) WO2017053346A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018172850A1 (en) * 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
CN111836615A (zh) * 2018-01-05 2020-10-27 英倍尔药业股份有限公司 通过精密鼻装置的奥氮平的鼻内递送
AU2020410549A1 (en) * 2019-12-20 2022-04-14 Alar Pharmaceuticals Inc. Long-acting injectable formulations of ketamine pamoate salts
CN112587505A (zh) * 2020-10-16 2021-04-02 长春斯菲尔生物科技有限公司 一种奥氮平双羟萘酸盐缓释微粒制剂及其制备方法
WO2025188992A1 (en) * 2024-03-06 2025-09-12 Neurelis, Inc. Oral film for rapid active delivery

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
EA002825B1 (ru) * 1997-09-30 2002-10-31 Эли Лилли Энд Компани Препарат 2-метилтиенобензодиазепина
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
DK1635875T3 (da) 2003-06-26 2009-01-12 Psivida Inc In-situ-geldannende lægemiddeladministrationssystem
KR101242486B1 (ko) 2004-01-12 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 장기 전달을 위한 제형 및 그의 이용 방법
EP1576952A1 (en) 2004-03-18 2005-09-21 OctoPlus Technologies B.V. Hydrogel microspheres with improved release profile
NL1026261C2 (nl) 2004-05-25 2005-11-28 Nanomi B V Sproei inrichting met een nozzleplaat voorzien van structuren ter bevordering van self-breakup, een nozzleplaat, alsmede werkwijzen ter vervaardiging en toepassing van een dergelijke nozzleplaat.
NZ551990A (en) 2004-06-04 2011-01-28 Camurus Ab Liquid depot formulations
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
EP1874267A1 (en) * 2005-04-13 2008-01-09 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
WO2006109183A1 (en) * 2005-04-13 2006-10-19 Pfizer Products Inc. Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ATE552032T1 (de) * 2005-07-14 2012-04-15 Lithera Inc Verbesserte lipolytikum-formulierung mit hinhaltender wirkstofffreigabe für die arealbehandlung von fettgewebe
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
FI20070174A0 (fi) 2007-02-28 2007-02-28 Delsitech Oy Menetelmä silikakoostumusten valmistamiseksi, silikakoostumukset ja niiden käytöt
KR100805208B1 (ko) 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA
US10010612B2 (en) 2007-05-25 2018-07-03 Indivior Uk Limited Sustained delivery formulations of risperidone compounds
ES2324009B1 (es) 2007-11-23 2010-05-21 Gp Pharm S.A. Composicion farmaceutica de liberacion sostenida de somatostatina o un analogo suyo.
JP5222550B2 (ja) * 2007-12-27 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
EP2309982A2 (en) 2008-06-03 2011-04-20 Tolmar Therapeutics, Inc. Controlled release copolymer formulation with improved release kinetics
KR101626632B1 (ko) 2008-08-12 2016-06-01 노파르티스 아게 제약 조성물
PT2355853T (pt) 2008-10-10 2017-03-15 Polyactiva Pty Ltd Conjugados polímero biodegradável ¿ unidade bioativa
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
US9561352B2 (en) 2009-03-12 2017-02-07 Delpor, Inc. Implantable device for long-term delivery of drugs
EP2485712A1 (en) 2009-10-06 2012-08-15 Ascendis Pharma A/S Subcutaneous paliperidone composition
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
EP2343046A1 (en) 2010-01-08 2011-07-13 Nirvana's Tree House B.V. Functionalised triblock copolymers and compositions containing such polymers
LT2394663T (lt) * 2010-05-31 2022-02-10 Laboratorios Farmaceuticos Rovi, S.A. Kompozicijos, skirtos įšvirkščiamiems in situ biologiškai skaidiems implantams
UA111162C2 (uk) 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
FR2968994B1 (fr) 2010-12-17 2012-12-28 Flamel Tech Sa Procede de preparation de nanoparticules
CN103491946B (zh) 2010-12-29 2016-08-10 美蒂森 可生物降解的药物释放组合物
SI2717914T1 (sl) 2011-06-10 2020-07-31 Ramscor Inc. Formulacije z zadržanim sproščanjem za dostavo proteinov v oko in postopki njihove priprave
MX350469B (es) 2011-10-24 2017-09-07 Endo Pharmaceuticals Solutions Composiciones para el suministro de farmacos implantables y metodos para su tratamiento.
MX364864B (es) 2012-01-23 2019-05-09 Allergan Inc Microesferas o microparticulas biodegradables o bioerosionables de liberacion progresiva suspendidas en una formulacion de farmaco inyectable de formacion de deposito solidificante.
CN103417492A (zh) * 2012-05-25 2013-12-04 上海现代药物制剂工程研究中心有限公司 含有奥氮平的生物降解微球制剂及其制备方法
US20140323517A1 (en) 2013-04-30 2014-10-30 Heron Therapeutics, Inc. Compositions and methods for injection of a biodegradable polymer-based delivery system
WO2014202214A1 (en) 2013-06-20 2014-12-24 Pharmathen S.A. Preparation of polylactide-polyglycolide microparticles having a sigmoidal release profile
CN103877005A (zh) * 2014-03-26 2014-06-25 陈德香 一种复方奥氮平皮下埋植缓释剂

Similar Documents

Publication Publication Date Title
US10195138B2 (en) Methods for the preparation of injectable depot compositions
JP2018527397A5 (cg-RX-API-DMAC7.html)
US10182982B2 (en) Antipsychotic injectable depot composition
KR101914119B1 (ko) 약물 전달용 이종 이식가능 장치
Lee et al. Biodegradable implants for sustained drug release in the eye
US10881605B2 (en) Methods for the preparation of injectable depot compositions
US11241377B2 (en) Antipsychotic injectable depot composition
CY1113253T1 (el) Δοσολογικο σχημα για τη θεραπευτικη αντιμετωπιση μιας τραυματικης εγκεφαλικης βλαβης με προγεστερονη
US9556333B2 (en) Biodegradable polymer formulations
WO2009129149A4 (en) Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
JP2013522314A5 (cg-RX-API-DMAC7.html)
KR20220029744A (ko) 신규 방법
JP2016074740A5 (cg-RX-API-DMAC7.html)
US9610243B2 (en) Clonidine compounds in a biodegradable polymer
NZ781622A (en) Method of treating a child with central precocious puberty using an extended release composition
MX2022000489A (es) Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.
JP2011508791A5 (cg-RX-API-DMAC7.html)
JP2016527308A (ja) エンテカビル微小球及びこれを含む非経口投与用医薬組成物
JP2019512495A5 (cg-RX-API-DMAC7.html)
RU2018130696A (ru) Оромукозные нановолоконные носители для терапевтического лечения
JP2018522920A5 (cg-RX-API-DMAC7.html)
CN110139668A (zh) 一种预防和治疗肝纤维化的方法
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
JP2020500930A5 (cg-RX-API-DMAC7.html)
BR112015011294A8 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco pentoxifilina de uso humano e uso destas